Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia

References

• Rea D, Cayuela JM Treatment-free remission in patients with chronic myeloid leukemia. [published online 8 July 2017] Int J Hematol. doi: 10.1007/s12185-017-2295-0.
   Google Scholar
• Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23. doi: 10.1182/blood-2016-01-694265.
   PubMed Web of Science ®Google Scholar
• Keating GM. Dasatinib: a review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia. Drugs. 2017;77:85–96. doi: 10.1007/s40265-016-0677-x.
   PubMed Web of Science ®Google Scholar
• Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner GH, Sperr WR, Kirchmair R, Wolf D. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. [published online 12 May 2017] Leuk Res. 2017;59:47–54. doi: 10.1016/j.leukres.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–4218. doi: 10.1200/JCO.2015.62.4718.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Ravandi F, O’Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115:2482–2490. doi: 10.1002/cncr.24257.
   PubMed Web of Science ®Google Scholar
• Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: case report. Platelets. 2015;26:809–811. doi: 10.3109/09537104.2015.1049138.
   PubMed Web of Science ®Google Scholar
• Ono Y, Mori T, Kato J, Yamane A, Yajima T, Iwao Y, Hibi T, Okamoto S. Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia. Int J Hematol. 2010;92:556–558. doi: 10.1007/s12185-010-0677-7.
   PubMed Web of Science ®Google Scholar
• Sartor C, Papayannidis C, Chiara Abbenante M, Iacobucci I, Broccoli A, Venturi C, Testoni N, Ferrari A, Martinelli G. Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing smad4 mutation with acute lymphoblastic leukemia philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome. Hematol Rep. 2013;5:26–27. doi: 10.4081/hr.2013.e7.
   PubMedGoogle Scholar
• Yim E, Choi YG, Nam YJ, Lee J, Kim JA. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia. Korean J Intern Med. 2017;69:308–311.
   Google Scholar
• Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261–263. doi: 10.1182/blood-2008-09-180604.
   PubMed Web of Science ®Google Scholar
• Levade M, Severin S, Gratacap MP, Ysebaert L, Payrastre B. Targeting kinases in cancer therapies: adverse effects on blood platelets. Curr Pharm Des. 2016;22:2315–2322.
   PubMed Web of Science ®Google Scholar
• Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95:1694–1702.
   PubMed Web of Science ®Google Scholar
• Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185–2192. doi: 10.1111/j.1538-7836.2005.01274.x.
   PubMed Web of Science ®Google Scholar
• Norgard NB, Saya S, Hann CL, Hennebry TA, Schechter E, Dale GL. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. J Cardiovasc Pharmacol. 2008;52:536–539. doi: 10.1097/FJC.0b013e3181907390.
   PubMed Web of Science ®Google Scholar
• Prodan CI, Joseph PM, Vincent AS, Dale GL. Coated-platelets in ischemic stroke: differences between lacunar and cortical stroke. J Thromb Haemost. 2008;6:609–614. doi: 10.1111/j.1538-7836.2008.02890.x.
   PubMed Web of Science ®Google Scholar
• Prodan CI, Vincent AS, Dale GL. Coated-platelet levels are elevated in patients with transient ischemic attack. Transl Res. 2011;158:71–75. doi: 10.1016/j.trsl.2011.02.010.
   PubMed Web of Science ®Google Scholar
• Prodan CI, Vincent AS, Dale GL. Coated-platelet levels correlate with bleed volume in patients with spontaneous intracerebral hemorrhage. Stroke. 2010;41:1301–1303. doi: 10.1161/STROKEAHA.110.581447.
   PubMed Web of Science ®Google Scholar
• Saxena K, Pethe K, Dale GL. Coated-platelet levels may explain some variability in clinical phenotypes observed with severe hemophilia. J Thromb Haemost. 2010;8:1140–1142. doi: 10.1111/j.1538-7836.2010.03828.x.
   PubMed Web of Science ®Google Scholar
• Brooks MB, Catalfamo JL, Friese P, Dale GL. Scott syndrome dogs have impaired coated-platelet formation and calcein release but normal mitochondrial depolarization. J Thromb Haemost. 2007;5:1972–1974. doi: 10.1111/j.1538-7836.2007.02683.x.
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, Gosmanova AK, Lyons TJ, May KD, Dashti A, Baker MZ, Olansky L, Aston CE, Dale GL. Coated-platelet levels in patients with Type 1 and with Type 2 diabetes mellitus. [published online 27 May 2008] Diabetes Res Clin Pract. doi: 10.1016/j.diabres.2008.04.004.
   Google Scholar
• Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury HJ, Khoroshko N, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322–6329. doi: 10.1182/blood-2008-11-186817.
   PubMed Web of Science ®Google Scholar
• Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85:164–170. doi: 10.1002/ajh.21615.
   PubMed Web of Science ®Google Scholar
• Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14:352–359. doi: 10.1158/1078-0432.CCR-07-4175.
   PubMed Web of Science ®Google Scholar
• Mustafa Ali MK, Sabha MM, Al-Rabi KH. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment. Platelets. 2015;26:491–494. doi: 10.3109/09537104.2014.935316.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Hatemi I, Öngören-Aydin S, Ar MC, Soysal T. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. Turk J Gastroenterol. 2014;25(Suppl.1): 233.
   PubMedGoogle Scholar
• Chisti MM, Khachani A, Brahmanday GR, Klamerus J Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis. [published online 12 December 2013] BMJ Case Rep. doi: 10.1136/bcr-2013-200610.
   Google Scholar
• Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, Monia Z, Sriha B, Abderrahim K. Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol. 2013;4:59–62. doi: 10.4291/wjgp.v4.i3.59.
   PubMedGoogle Scholar
• Dale GL. Procoagulant platelets: Further details but many more questions. Arterioscler Thromb Vasc Biol. 2017;37:1596–1597. doi: 10.1161/ATVBAHA.117.309847.
   PubMed Web of Science ®Google Scholar
• Prodan CI, Stoner JA, Cowan LD, Dale GL. Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction. J Cereb Blood Flow Metab. 2013;33:287–292. doi: 10.1038/jcbfm.2012.168.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick AC, Tafur AJ, Vincent AS, Dale GL, Prodan CI. Coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis. Stroke. 2014;45:2995–3001. doi: 10.1161/STROKEAHA.114.006492.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick AC, Vincent AS, Dale GL, Prodan CI. Coated-platelets predict stroke at 30 days following TIA. Neurology. 2017;89:125–128. doi: 10.1212/WNL.0000000000004090.
   PubMed Web of Science ®Google Scholar
• Polgár J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TN, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem. 1997; 272: 13576–13583.
   PubMed Web of Science ®Google Scholar
• Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. Blood. 2014;124:2013–2024. doi: 10.1182/blood-2014-01-453134.
   PubMed Web of Science ®Google Scholar
• Huang MM, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci U S A. 1991;88:7844–7848.
   PubMed Web of Science ®Google Scholar
• Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med. 1998;188:267–276.
   PubMed Web of Science ®Google Scholar
• Giles FJ, O’Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23:1698–1707. doi: 10.1038/leu.2009.111.
   PubMed Web of Science ®Google Scholar
• Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol. 2013;5:85–97. doi: 10.2147/CPAA.S42796.
   PubMedGoogle Scholar
• Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38:645–654. doi: 10.1248/bpb.b15-00103.
   PubMed Web of Science ®Google Scholar
• Gratacap MP, Martin V, Valéra MC, Allart S, Garcia C, Sié P, Recher C, Payrastre B. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114:1884–1892. doi: 10.1182/blood-2009-02-205328.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Maeda M, Yamada M, Okuno S, Harada Y, Suzuki K, Kurahashi S, Urano F, Okamura S, Sugiura I. Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients. Blood. 2017;129:126–128. doi: 10.1182/blood-2016-08-734947.
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Colom-Fernández B, Jiménez AM, Ilander M, Cuesta-Mateos C, Pérez-García Y, Arévalo CD, Brück O, Hakanen H, Saarela J, et al. Disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner. Clin Cancer Res. 2017;23:6697–6707. doi: 10.1158/1078-0432.CCR-16-0667.
   PubMed Web of Science ®Google Scholar